All
NATALEE Trial Evaluates Ribociclib With ET in Early Breast Cancer
May 20th 2024Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.
Dhakal on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
May 17th 2024Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least 1 prior line of therapy and is refractory to lenalidomide.
Unlocking the Potential of Technology in Community Oncology
In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.